DESCRIPTION
Technicalfieldofinvention:
|0002| The invention generally relates to the continuous monitoring of human fatty liver using Nano Graphene Polyvinyl sensor.
Backgroundof theinvention:
[0003] To measure the mechanical and tissue property of the fatty liver, signal from the liver obtained through the nano sensor during the extreme inhale and exhale. The inhale leads to deformation of liver and creates the stiffness in liver tissues and exhale inhomogeneous distribution of fat in the liver is vibrated. The fatty liver volume is measured using blind source separation of signals is applied and differentiates the liver and fatty region signals. To measure the fatty liver volume, from digitized signals of liver, Nonnegative Matrix Filter extract fat signal. Fat signal instantaneous frequency is obtained and correlatewith lab values. Gaussian regression process is used for fatty liver prediction. The proposed method of fatty liver volume measurement ultrasound images of liver and phantom is used.
[0004] • The Patent No.US10001468B2titled "Biomarkers for differentiating between non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD)" discloses a invention provides biomarkers and a method for differentiating between Non Alcoholic Steatohepatitis and Non Alcoholic Fatty Liver Disease

[00051 The Patent No .EP2607902B1 titled "Markers of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) and methods of use thereof The invention provides a method of diagnosing or monitoring non-alcoholic fatty liver disease (NAFLD) in a subject, to determine the amount of one or more lipid metabolites in one or more plasma samples from the subject, methods of assessing the level of accumulation of triglycerides in the liver of a subject (e.g., a human) and/or monitoring, diagnosing, classifying, assessing the severity, and/or assessing the progression or regression of a liver disorder in the subject. In some embodiments, the liver disorder is hepatic impairment, hepatic steatosis, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, or non-alcoholic steatohepatitis (NASH). In some embodiments, the methods comprise determining the amount of one or more lipid metabolites (e.g., fatty acids and/or eicosanoids) in a body fluid from the subject.
[0006] The Patent No.US10925885B2titled "Thyromimetics for the treatment of fatty liver diseases" discloses a thyromimetic compounds that are thyroid receptor ligands. This thyroid receptor pharmaceutically acceptable salts and prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis.
[0007] • The Patent No.AU20l9206030B2titled "Methods of treating fatty liver disease" discloses the compositions and methods for treating five fatty liver disease by administering an antagonist of an ActRJIB signaling pathway. The antagonists include ActRlIB polypeptides, ant-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies and anti-activin A or B antibodies. The hepatic and metabolic siorders are improved by treating fatty liver disease.
[0009] The Patent No.US020170281593Altitled "Methods of Treating Fatty Liver Disease"
discloses a the inhibition of the synthesis of glucosphingolipidssuch as ganglioside GM3
in the liver. The invention relates the use of inhibitors of glucosphingo lipid synthesis,
such as glucosylceramide synthase, lactosylceramidesynthase and GM3 synthase for the
. treatment of fatty liver disease and associated conditions.

Summarvof theinvention:
[0010] Human fatty liver volume is measured through Nano Graphene Polyvinyl (NGP) sensor. NGP sensor acquires the scattering electromagnetic rays from fatty liver, which arises due to dielectric property of fat. The continuous monitoring of fatty liver volume through the dielectric property of fat tissues helps to understand the prognosis of fatty liver diseases such as fibrosis, cirrhosis, alcoholic'hepatitis, hepatic steatosis and steatohepatitis, leads to correlate with other disease such as diabetes and cardiac ailments.
[0011] Monitoring of fatty liver volume through various imaging techniques such as ultrasound MRI and CT is time consuming, leads to exposure of harmful radiation and high cost. The existing imaging techniques measures the fatty liver volume, whereas continuous monitoring is never feasible through imaging modalities.
[0012] The problem of continuous monitoring of fatty liver volume is solved through NGP sensor, which is fabricated through spray pyrolysis method and consist of various materials such as nano graphene, Poly acrylic acid, Methylenbisacrylamide (MBAAm), 2,2-dimethoxy-2- phenylacetophenone (DMPAP) Poly vinyl acetate. NGP sensor is fixed on the human liver surface and acquires scattering electromagnetic signal.
100131 The acquired signal is processed with NMF blind source separation for removing random motion noise and extracts fatty liver signals. From the fatty liver signal, instantaneous frequency is obtained through Multi Synchro Squeezing Transform. Furthermore, fatty liver volume is measured through instantaneous frequency and Gaussian Regression model. From the experimental results, the proposed NGP sensor fatty liver level measurement is validated through ultrasound images and provides an accuracy of about 85% in prediction.
Briefdescription ofdrawing:
[0014] The proposed Nano Graphene Polyvinyl sensor absorbs radiation from the fat. The fat content measured from fatty liver consist of different artifacts namely artifacts due to air bubbles, motion artifacts and unsealed noise added during signal transmission through WiFi. The artifacts in acquired signals are removed by using blind search separation. FL

has major portion of triglycerides and other components such as mono and diglycerides are in negligible amount. Dielectric radiation from fatty liver due to triglycerides acquired through Nano Graphene Polyvinyl sensor, and artifacts along with acquired signal is removed through blind source separation method. The Blind source method help to separate fat emitted electromagnetic ray due to dielectric material on the liver surface. NGP signal obtained from rabbit
[0015] FIG 1 illustrates a methodology for Nanographene Polyvinyl Sensor for fatty liver . monitoring.
[0016] FIG 2 illustrates the Data acquisition of signal from Nano Graphene Polyvinyl Sensor.
[0017] FIG 3illustrates fatty liver volume measurement through instantaneous frequency. DetaHeddescrintion of theinvention:
[0018] The subjects are made to settle in one place and Nanographene polyvinyl textile sensoris
placed in the liver region where the liver is present.The hardware design is connected to
the leads. Nano Graphene Polyvinyl sensor is placed on fatty liver person and radiation
intensity observed by Nano Graphene Polyvinyl sensor according to fat content in the
■ liver, sharing.
[0019] Nano Graphene Polyvinyl sensor signal acquires the dielectric constant present in the fat. The signal that is acquired from the sensor is passed through a filter which are of varying orders.The acquired signal is recorded and analyzed in software platforms such as MATLAB based on the additional add on software packages that are required.
[0020] Certain time-based features and frequency-based features are extracted from the data sets
of the normal and diseased subjects.Correlation between the features is estimated for
diagnosing the fatty liver stages and the design efficiency of the hardware prototype.
Thus this method of diagnosis gives a non-invasive approach towards fatty liver
. disorders.
[0021] The Gaussian regression modelling is used for predicting the fatty livers levels. Micro Synchro Squeezing value obtained from proposed Nano Graphene Polyvinyl sensor is